|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
PL4023249T3
(pl)
|
2014-04-23 |
2025-03-10 |
Modernatx, Inc. |
Szczepionki z kwasem nukleinowym
|
|
HUE060907T2
(hu)
*
|
2014-06-25 |
2023-04-28 |
Acuitas Therapeutics Inc |
Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
|
|
EP4353257A3
(en)
|
2015-04-13 |
2024-08-07 |
CureVac Manufacturing GmbH |
Method for producing rna compositions
|
|
AU2016253972B2
(en)
|
2015-04-27 |
2020-01-02 |
Acuitas Therapeutics Inc. |
Nucleoside-modified RNA for inducing an adaptive immune response
|
|
PT3313829T
(pt)
|
2015-06-29 |
2024-07-08 |
Acuitas Therapeutics Inc |
Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos
|
|
MA42502A
(fr)
|
2015-07-21 |
2018-05-30 |
Modernatx Inc |
Vaccins contre une maladie infectieuse
|
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
|
JP6948313B6
(ja)
*
|
2015-09-17 |
2022-01-14 |
モデルナティエックス インコーポレイテッド |
治療剤の細胞内送達のための化合物および組成物
|
|
WO2017070624A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Tropical disease vaccines
|
|
AU2016342376A1
(en)
|
2015-10-22 |
2018-06-07 |
Modernatx, Inc. |
Sexually transmitted disease vaccines
|
|
WO2017070601A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
HRP20230209T1
(hr)
*
|
2015-10-28 |
2023-04-14 |
Acuitas Therapeutics Inc. |
Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
|
|
PL3386484T3
(pl)
*
|
2015-12-10 |
2022-07-25 |
Modernatx, Inc. |
Kompozycje i sposoby dostarczania środków terapeutycznych
|
|
LT3394030T
(lt)
|
2015-12-22 |
2022-04-11 |
Modernatx, Inc. |
Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu
|
|
WO2017201342A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding jagged1 for the treatment of alagille syndrome
|
|
US11001861B2
(en)
|
2016-05-18 |
2021-05-11 |
Modernatx, Inc. |
Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
|
|
CA3040337A1
(en)
*
|
2016-10-26 |
2018-05-03 |
Curevac Ag |
Lipid nanoparticle mrna vaccines
|
|
EP3532103B1
(en)
*
|
2016-10-26 |
2025-12-03 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
CN110402145A
(zh)
*
|
2016-10-26 |
2019-11-01 |
莫得纳特斯公司 |
用于增强免疫应答的信使核糖核酸及其使用方法
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
US20190274968A1
(en)
*
|
2016-10-27 |
2019-09-12 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
|
AU2017356699B2
(en)
|
2016-11-08 |
2021-11-11 |
Ramot At Tel-Aviv University Ltd. |
Cationic lipids for nucleic acid delivery and preparation thereof
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
MA46766A
(fr)
|
2016-11-11 |
2019-09-18 |
Modernatx Inc |
Vaccin antigrippal
|
|
WO2018107088A2
(en)
*
|
2016-12-08 |
2018-06-14 |
Modernatx, Inc. |
Respiratory virus nucleic acid vaccines
|
|
AU2017374042C1
(en)
*
|
2016-12-09 |
2024-07-11 |
Acuitas Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
CA3049991A1
(en)
|
2017-01-11 |
2018-07-19 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an immune response against zika virus
|
|
BR112019015797A2
(pt)
|
2017-02-01 |
2020-03-17 |
Modernatx, Inc. |
Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação
|
|
TW202428301A
(zh)
|
2017-02-28 |
2024-07-16 |
法商賽諾菲公司 |
治療性rna
|
|
WO2018170245A1
(en)
*
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
WO2018170322A1
(en)
*
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
|
EP4186888B1
(en)
|
2017-03-15 |
2025-11-26 |
ModernaTX, Inc. |
Compound and compositions for intracellular delivery of therapeutic agents
|
|
EP3595713A4
(en)
|
2017-03-15 |
2021-01-13 |
ModernaTX, Inc. |
RESPIRATORY SYNCYTIAL VIRUS Vaccine
|
|
CA3055653A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
|
WO2018170270A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Varicella zoster virus (vzv) vaccine
|
|
WO2018170256A1
(en)
*
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
EP3595676A4
(en)
|
2017-03-17 |
2021-05-05 |
Modernatx, Inc. |
RNA VACCINES AGAINST ZOONOSES
|
|
WO2018175783A1
(en)
*
|
2017-03-22 |
2018-09-27 |
Modernatx, Inc. |
Rna bacterial vaccines
|
|
WO2018188730A1
(en)
*
|
2017-04-11 |
2018-10-18 |
Biontech Rna Pharmaceuticals Gmbh |
Rna for treatment of autoimmune diseases
|
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
US11596679B2
(en)
*
|
2017-04-27 |
2023-03-07 |
Vanderbilt University |
Hepatitis C virus gene sequences and methods of use therefor
|
|
CN110799492B
(zh)
*
|
2017-04-28 |
2023-06-27 |
爱康泰生治疗公司 |
用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
|
|
WO2018232120A1
(en)
|
2017-06-14 |
2018-12-20 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
WO2018232355A1
(en)
*
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna antibodies
|
|
CA3073020A1
(en)
|
2017-08-16 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
AU2018316811B2
(en)
|
2017-08-17 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof
|
|
EP4501322A3
(en)
*
|
2017-08-17 |
2025-04-16 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
US20200254086A1
(en)
*
|
2017-08-18 |
2020-08-13 |
Moderna TX, Inc. |
Efficacious mrna vaccines
|
|
WO2019055807A1
(en)
|
2017-09-14 |
2019-03-21 |
Modernatx, Inc. |
RNA VACCINES AGAINST ZIKA VIRUS
|
|
EP3746090A4
(en)
|
2018-01-29 |
2021-11-17 |
ModernaTX, Inc. |
RSV RNA Vaccines
|
|
WO2020061367A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
IL281615B2
(en)
|
2018-09-21 |
2026-01-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
CA3116576A1
(en)
|
2018-10-18 |
2020-04-23 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
PT3908568T
(pt)
|
2019-01-11 |
2024-09-30 |
Acuitas Therapeutics Inc |
Lípidos para a administração de agentes ativos por nanopartículas lipídicas
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
US12070495B2
(en)
|
2019-03-15 |
2024-08-27 |
Modernatx, Inc. |
HIV RNA vaccines
|
|
US11098002B2
(en)
|
2019-07-26 |
2021-08-24 |
Espervita Therapeutics, Inc. |
Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease
|
|
WO2021050989A1
(en)
|
2019-09-13 |
2021-03-18 |
Duke University |
Zika antibodies and their use
|
|
AU2020350759A1
(en)
|
2019-09-19 |
2022-03-31 |
Modernatx, Inc. |
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
CA3155015A1
(en)
|
2019-09-19 |
2021-03-25 |
Modernatx, Inc. |
Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
EP4048807A1
(en)
|
2019-09-23 |
2022-08-31 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating apolipoprotein b (apob) gene expression
|
|
CN114729376A
(zh)
|
2019-09-23 |
2022-07-08 |
欧米茄治疗公司 |
用于调节肝细胞核因子4α(HNF4α)基因表达的组合物和方法
|
|
JP2022552378A
(ja)
*
|
2019-10-15 |
2022-12-15 |
モデルナティエックス インコーポレイテッド |
パーキンソン病を治療するための顆粒球マクロファージコロニー刺激因子をコードするｍＲＮＡ
|
|
US12559527B2
(en)
|
2019-10-23 |
2026-02-24 |
Duke University |
Compositions comprising V2 opt HIV envelopes
|
|
KR102769095B1
(ko)
*
|
2019-11-07 |
2025-02-18 |
주식회사 삼양홀딩스 |
면역유도용 고분자 나노입자 조성물 및 그 제조방법
|
|
CN114901360A
(zh)
|
2019-12-20 |
2022-08-12 |
库瑞瓦格股份公司 |
用于递送核酸的新型脂质纳米颗粒
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
CA3173528A1
(en)
|
2020-03-11 |
2021-09-16 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
|
|
KR20230104068A
(ko)
*
|
2020-03-31 |
2023-07-07 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
뉴클레오사이드 변형 mRNA를 사용한 범용 인플루엔자 백신
|
|
EP4132576A1
(en)
|
2020-04-09 |
2023-02-15 |
Suzhou Abogen Biosciences Co., Ltd. |
Nucleic acid vaccines for coronavirus
|
|
FI20215508A1
(en)
|
2020-04-09 |
2021-10-10 |
Niemelae Erik Johan |
Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection
|
|
WO2021204175A1
(en)
*
|
2020-04-09 |
2021-10-14 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid nanoparticle composition
|
|
US12194157B2
(en)
|
2020-04-09 |
2025-01-14 |
Finncure Oy |
Carrier for targeted delivery to a host
|
|
IL297419B2
(en)
|
2020-04-22 |
2025-02-01 |
BioNTech SE |
Coronavirus vaccine
|
|
KR20230030588A
(ko)
|
2020-06-30 |
2023-03-06 |
쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 |
지질 화합물 및 지질 나노입자 조성물
|
|
EP4178544A4
(en)
*
|
2020-07-08 |
2024-09-25 |
The Trustees of the University of Pennsylvania |
NUCLEOSIDE-MODIFIED RNA TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV-2 VIRUS
|
|
ES3054438T3
(en)
*
|
2020-07-16 |
2026-02-03 |
Acuitas Therapeutics Inc |
Cationic lipids for use in lipid nanoparticles
|
|
CN114073677B
(zh)
*
|
2020-08-20 |
2023-06-09 |
深圳深信生物科技有限公司 |
一种脂质纳米颗粒
|
|
CN114391008B
(zh)
*
|
2020-08-20 |
2024-05-03 |
苏州艾博生物科技有限公司 |
脂质化合物和脂质纳米颗粒组合物
|
|
US12419948B2
(en)
|
2020-08-31 |
2025-09-23 |
The Broad Institute, Inc. |
Immunogenic compositions and use thereof
|
|
WO2022081702A1
(en)
*
|
2020-10-13 |
2022-04-21 |
The Trustees Of The University Of Pennsylvania |
In vivo targeting of cd4+-t cells for mrna therapeutics
|
|
EP4228658A4
(en)
|
2020-10-14 |
2025-02-19 |
George Mason Research Foundation, Inc. |
IONIZABLE LIPIDS AND METHODS FOR THE PRODUCTION AND USE THEREOF
|
|
WO2022099003A1
(en)
|
2020-11-06 |
2022-05-12 |
Sanofi |
Lipid nanoparticles for delivering mrna vaccines
|
|
WO2022101486A1
(en)
|
2020-11-16 |
2022-05-19 |
BioNTech SE |
Pharmaceutical compositions comprising particles and mrna and methods for preparing and storing the same
|
|
TW202237148A
(zh)
|
2020-11-16 |
2022-10-01 |
德商拜恩迪克公司 |
包含rna之lnp組合物以及製備、儲存及使用彼之方法
|
|
WO2022218503A1
(en)
|
2021-04-12 |
2022-10-20 |
BioNTech SE |
Lnp compositions comprising rna and methods for preparing, storing and using the same
|
|
WO2022115645A1
(en)
|
2020-11-25 |
2022-06-02 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids, and related methods of use
|
|
CN113185421B
(zh)
*
|
2020-11-27 |
2022-01-25 |
广州市锐博生物科技有限公司 |
脂质化合物及其组合物
|
|
WO2022112855A1
(en)
*
|
2020-11-27 |
2022-06-02 |
Guangzhou Ribobio Co., Ltd |
Lipid compound and the composition thereof
|
|
JP7419542B2
(ja)
*
|
2020-11-27 |
2024-01-22 |
グアンジョウ リボビオ カンパニー リミテッド |
脂質化合物及びその組成物
|
|
PH12023500013A1
(en)
*
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
US11918643B2
(en)
|
2020-12-22 |
2024-03-05 |
CureVac SE |
RNA vaccine against SARS-CoV-2 variants
|
|
WO2022152141A2
(en)
|
2021-01-14 |
2022-07-21 |
Suzhou Abogen Biosciences Co., Ltd. |
Polymer conjugated lipid compounds and lipid nanoparticle compositions
|
|
WO2022152109A2
(en)
|
2021-01-14 |
2022-07-21 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
WO2022153187A1
(en)
*
|
2021-01-15 |
2022-07-21 |
Pfizer Inc. |
Methods for producing of lipids
|
|
CA3209453A1
(en)
|
2021-01-25 |
2022-07-28 |
Espervita Therapeutics, Inc. |
Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives therof, and their use for the prevention or treatment of disease
|
|
AU2022256732A1
(en)
|
2021-04-12 |
2023-10-19 |
Biontech Delivery Technologies Gmbh |
Rna compositions comprising a buffer substance and methods for preparing, storing and using the same
|
|
KR20240013087A
(ko)
|
2021-05-24 |
2024-01-30 |
쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 |
지질 화합물 및 지질 나노입자 조성물
|
|
EP4183770A1
(en)
|
2021-11-22 |
2023-05-24 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Continuous flow process for production of cationic lipids
|
|
WO2022269041A1
(en)
|
2021-06-24 |
2022-12-29 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Continuous flow process for production of cationic lipids
|
|
CA3224943A1
(en)
*
|
2021-07-06 |
2023-01-12 |
Erin Kathleen Reagan |
P7 containing nucleoside-modified mrna-lipid nanoparticle lineage vaccine for hepatitis c virus
|
|
EP4367242A2
(en)
|
2021-07-07 |
2024-05-15 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
|
CN115703713B
(zh)
*
|
2021-08-13 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
US20250114439A1
(en)
*
|
2021-08-18 |
2025-04-10 |
The Trustees Of The University Of Pennsylvania |
mRNA VACCINES AGAINST TICK SALIVARY PROTEINS, AND METHODS OF USING SAME
|
|
US20240398933A1
(en)
|
2021-09-03 |
2024-12-05 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
|
|
US20240398940A1
(en)
|
2021-09-03 |
2024-12-05 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids
|
|
CA3229889A1
(en)
|
2021-09-03 |
2023-03-09 |
Glaxosmithkline Biologicals Sa |
Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids
|
|
TW202328067A
(zh)
*
|
2021-09-14 |
2023-07-16 |
美商雷納嘉德醫療管理公司 |
環狀脂質及其使用方法
|
|
CN116064598B
(zh)
|
2021-10-08 |
2024-03-12 |
苏州艾博生物科技有限公司 |
冠状病毒的核酸疫苗
|
|
AR127312A1
(es)
|
2021-10-08 |
2024-01-10 |
Suzhou Abogen Biosciences Co Ltd |
Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
|
|
JP2024536406A
(ja)
|
2021-10-08 |
2024-10-04 |
スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド |
脂質化合物及び脂質ナノ粒子組成物
|
|
EP4422698A1
(en)
|
2021-10-29 |
2024-09-04 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
|
US12186387B2
(en)
|
2021-11-29 |
2025-01-07 |
BioNTech SE |
Coronavirus vaccine
|
|
CA3242402A1
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
JP2025502599A
(ja)
|
2021-12-23 |
2025-01-28 |
スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド |
脂質化合物及び脂質ナノ粒子組成物
|
|
TW202330457A
(zh)
*
|
2022-01-19 |
2023-08-01 |
大陸商蘇州艾博生物科技有限公司 |
脂質化合物和脂質奈米顆粒組合物
|
|
CN116554125B
(zh)
*
|
2022-01-27 |
2024-04-05 |
广州立得生物医药科技有限公司 |
一种阳离子脂质类似物、其组合物及应用
|
|
US20250099614A1
(en)
|
2022-01-28 |
2025-03-27 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
WO2023143600A1
(zh)
*
|
2022-01-30 |
2023-08-03 |
康希诺生物股份公司 |
一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗
|
|
WO2023165681A1
(en)
|
2022-03-01 |
2023-09-07 |
BioNTech SE |
Rna lipid nanoparticles (lnps) comprising a polyoxazoline and/or polyoxazine polymer
|
|
KR20240166554A
(ko)
*
|
2022-03-25 |
2024-11-26 |
세일 바이오메디슨스, 인크. |
신규한 이온화 가능 지질 및 지질 나노입자, 및 이를 사용하는 방법
|
|
WO2023193892A1
(en)
|
2022-04-05 |
2023-10-12 |
BioNTech SE |
Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same
|
|
AU2023268051A1
(en)
|
2022-05-13 |
2025-01-02 |
BioNTech SE |
Rna compositions targeting hiv
|
|
US20250345407A1
(en)
|
2022-05-25 |
2025-11-13 |
CureVac SE |
Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
|
|
CA3256897A1
(en)
|
2022-05-25 |
2023-11-30 |
Akagera Medicines, Inc. |
Lipid nanoparticles for the administration of nucleic acids and their methods of use
|
|
JP2025522297A
(ja)
|
2022-05-25 |
2025-07-15 |
ビオンテック エスエー |
サルポックス抗原の送達のためのｒｎａ組成物及び関連する方法
|
|
JP2025518221A
(ja)
|
2022-05-30 |
2025-06-12 |
ビオンテック・ソシエタス・エウロパエア |
核酸の送達のための複合体
|
|
WO2023242817A2
(en)
|
2022-06-18 |
2023-12-21 |
Glaxosmithkline Biologicals Sa |
Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2
|
|
CN114989182B
(zh)
*
|
2022-06-23 |
2023-06-23 |
尧唐(上海)生物科技有限公司 |
脂质化合物、包含其的组合物及应用
|
|
WO2024002985A1
(en)
|
2022-06-26 |
2024-01-04 |
BioNTech SE |
Coronavirus vaccine
|
|
CN119731150A
(zh)
*
|
2022-07-15 |
2025-03-28 |
深圳深信生物科技有限公司 |
一种氨基脂质化合物、其制备方法、组合物和应用
|
|
AU2023317702A1
(en)
|
2022-08-01 |
2025-01-09 |
BioNTech SE |
Nucleic acid compositions comprising amphiphilic oligo ethylene glycol (oeg)-conjugated compounds and methods of using such compounds and compositions
|
|
WO2024083345A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Methods and uses associated with liquid compositions
|
|
EP4608442A1
(en)
|
2022-10-28 |
2025-09-03 |
GlaxoSmithKline Biologicals S.A. |
Nucleic acid based vaccine
|
|
WO2024094098A1
(zh)
*
|
2022-11-02 |
2024-05-10 |
益杰立科(上海)生物科技有限公司 |
一种用于递送系统的化合物及其用途
|
|
WO2024133160A1
(en)
|
2022-12-19 |
2024-06-27 |
Glaxosmithkline Biologicals Sa |
Hepatitis b compositions
|
|
AU2023413766A1
(en)
|
2022-12-23 |
2025-05-29 |
Biontech Delivery Technologies Gmbh |
Composition
|
|
WO2024144267A1
(ko)
*
|
2022-12-27 |
2024-07-04 |
(주)한국바이오셀프 |
Hiv-1 mrna를 포함하는 백신 조성물
|
|
EP4642797A1
(en)
|
2022-12-28 |
2025-11-05 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2024163918A1
(en)
|
2023-02-02 |
2024-08-08 |
University Of Houston System |
Mrna vaccine for herpes simplex virus
|
|
WO2024184500A1
(en)
|
2023-03-08 |
2024-09-12 |
CureVac SE |
Novel lipid nanoparticle formulations for delivery of nucleic acids
|
|
WO2024193827A1
(en)
|
2023-03-23 |
2024-09-26 |
BioNTech SE |
Stabilized nucleic acid compositions and methods for preparing, storing and using the same
|
|
CN118845700A
(zh)
*
|
2023-04-29 |
2024-10-29 |
康希诺(上海)生物研发有限公司 |
一种用于递送核酸药物的脂质纳米颗粒及其制备方法和用途
|
|
US12502424B2
(en)
|
2023-05-05 |
2025-12-23 |
Sanofi Pasteur Inc. |
Compositions for use in treatment of acne
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
EP4716741A2
(en)
|
2023-05-23 |
2026-04-01 |
Flagship Labs 114, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
|
EP4734960A1
(en)
|
2023-06-28 |
2026-05-06 |
Sanofi Pasteur Inc. |
Sterol analogs in lipid nanoparticle formulations
|
|
WO2025030103A1
(en)
|
2023-08-03 |
2025-02-06 |
The Trustees Of The University Of Pennsylvania |
Rna compositions encoding herpes simplex virus glycoprotein b antigens and uses thereof
|
|
AU2024318951A1
(en)
|
2023-08-03 |
2026-03-12 |
BioNTech SE |
Rna compositions encoding herpes simplex virus glycoprotein e and/or glycoprotein i antigens and uses thereof
|
|
WO2025027579A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
CN121866336A
(zh)
|
2023-08-03 |
2026-04-14 |
百欧恩泰欧洲股份公司 |
靶向hiv的rna组合物
|
|
CN121729225A
(zh)
|
2023-08-25 |
2026-03-24 |
埃泽瑞斯公司 |
具有增强药物应用的特定表面活性剂性质的稳定脂质和类脂质纳米颗粒制剂
|
|
WO2025072383A1
(en)
|
2023-09-25 |
2025-04-03 |
The Broad Institute, Inc. |
Viral open reading frames, uses thereof, and methods of detecting the same
|
|
WO2025072921A1
(en)
*
|
2023-09-29 |
2025-04-03 |
Icahn School Of Medicine At Mount Sinai |
Chimeric influenza virus hemagglutinin mrna-based vaccines and uses thereof
|
|
CN119330848B
(zh)
*
|
2023-10-19 |
2025-07-08 |
仁景(苏州)生物科技有限公司 |
用于递送的脂质化合物及脂质纳米颗粒
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
US20250161227A1
(en)
|
2023-11-17 |
2025-05-22 |
Acuitas Therapeutics, Inc. |
Pegylated lipids
|
|
WO2025128696A1
(en)
|
2023-12-12 |
2025-06-19 |
Acuitas Therapeutics, Inc. |
Cationic lipid compounds for use in lipid nanoparticles
|
|
WO2025124711A1
(en)
|
2023-12-13 |
2025-06-19 |
BioNTech SE |
Glycolipid compositions
|
|
WO2025132122A1
(en)
|
2023-12-13 |
2025-06-26 |
Berlin Institute Of Health |
Methods of delivering therapeutics using lipid nanoparticles
|
|
WO2025126071A1
(en)
|
2023-12-14 |
2025-06-19 |
Pfizer Inc. |
Rna molecules
|
|
WO2025129158A1
(en)
|
2023-12-15 |
2025-06-19 |
The Broad Institute, Inc. |
Engineered arc delivery vesicles and uses thereof
|
|
WO2025141521A1
(en)
|
2023-12-29 |
2025-07-03 |
Sanofi |
Lipids having dendritic moieties
|
|
WO2025161943A1
(zh)
*
|
2024-02-02 |
2025-08-07 |
仁景(苏州)生物科技有限公司 |
用于递送的脂质化合物和脂质纳米颗粒
|
|
WO2025174858A1
(en)
|
2024-02-15 |
2025-08-21 |
Acuitas Therapeutics, Inc. |
Cationic lipid compounds for use in lipid nanoparticles
|
|
WO2025184508A1
(en)
|
2024-03-01 |
2025-09-04 |
Acuitas Therapeutics, Inc. |
Materials and methods for encapsulating therapeutics in lipid nanoparticles
|
|
WO2025186725A2
(en)
|
2024-03-06 |
2025-09-12 |
Pfizer Inc. |
Improved lnp formulations and uses thereof
|
|
WO2025217264A1
(en)
|
2024-04-10 |
2025-10-16 |
Acuitas Therapeutics, Inc. |
Cationic lipid compounds for use in lipid nanoparticles
|
|
WO2025229572A1
(en)
|
2024-05-01 |
2025-11-06 |
Glaxosmithkline Biologicals Sa |
Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines
|
|
WO2025240833A1
(en)
|
2024-05-17 |
2025-11-20 |
Acuitas Therapeutics, Inc. |
Galnac lipid compounds for use in lipid nanoparticles
|
|
WO2025255393A1
(en)
|
2024-06-06 |
2025-12-11 |
The Trustees Of The University Of Pennsylvania |
Herpes simplex virus antigen binding agents for mitigation of herpes simplex virus associated disease
|
|
WO2026018181A1
(en)
|
2024-07-17 |
2026-01-22 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
|
WO2026053147A1
(en)
|
2024-09-05 |
2026-03-12 |
Sanofi Pasteur Inc. |
Helper lipids and lnp compositions comprising same
|